CTIX Key Stats
- CELLCEUTIX CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountan... Jun 5
- InPlay: Cellceutix Presents poster at ASCO on its clinical trial of anti-cancer ... Jun 3
- Cellceutix Presents Poster at ASCO on Its Clinical Trial of Anti-Cancer Drug Kev... Jun 3
- As Pfizer Eyes It, Celgene Calls Cellceutix May 31
- Cellceutix to Present Poster on Novel Anti-Cancer Drug at Annual ASCO Meeting Marketwired May 28
- 3 Small Cap Cancer Stocks With Upcoming Catalysts May 20
- CELLCEUTIX CORP Files SEC form 10-Q, Quarterly Report May 20
- Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived May 9
- Potential 200% Return With Cellceutix Apr 22
- Coach Jim Boeheim Putting Up His Best Defense Against Michigan... and Cancer Marketwire Apr 5
CTIX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Cellceutix Corporation is up 148.6% over the last year vs S&P 500 Total Return up 25.82%, Synta Pharmaceuticals down 30.56%, and ARCA biopharma down 56.19%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CTIX
Pro Report PDF for CTIX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CTIX Pro Report PDF
Pro Strategies Featuring CTIX
Did Cellceutix Corporation make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.